Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

Movement Disorders

Volumn 25, Issue 16, 2010, Pages 2717-2723

  Sossi, Vesna ^a   De La Fuente Fernández, Raul ^b   Nandhagopal, Ramachandiran ^b   Schulzer, Michael ^b   McKenzie, Jessamyn ^b   Ruth, Thomas J ^c   Aasly, Jan O ^d   Farrer, Matthew J ^e   Wszolek, Zbigniew K ^f   Stoessl, Jon A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pacific Parkinson's Research Centre   (Canada)

^c TRIUMF   (Canada)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e MAYO GRADUATE SCHOOL   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Dopamine turnover; LRRK2 mutation; Parkinson's disease; PET imaging

Indexed keywords

6 FLUORODOPA F 18; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; ISOTOPE; LEUCINE RICH REPEAT KINASE 2; METHYLPHENIDATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MALE; MUTATIONAL ANALYSIS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; TURNOVER TIME;

ADULT; AGED; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN-SERINE-THREONINE KINASES; STATISTICS, NONPARAMETRIC;

EID: 78650209340     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23356     Document Type: Article

References (38)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
2. Bezard E, Gross CE. Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach. Prog Neurobiol 1998; 55: 93-116.
3. Zigmond MJ, Abercrombie ED, Berger, et al. Compensatory responses to partial loss of dopaminergic neurons: studies with 6-hydroxydopamine. In: Schneider JS, Gupta M, editors. Current concepts in Parkinson's disease research. Toronto: Hogrefe and Huber; 1993. p 99-140.
4. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128: 2777-2785.
5. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
6. 18F-fluorodopa data. J Cereb Blood Flow Metab 2002; 22: 232-239.
7. Nandhagopal RMak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008; 71: 1790-1795.
8. Lin CH, Tzen KY, Yu CY, et al. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. J Biomed Sci 2008; 15: 661-667.
9. Sossi V, de la Fuente-Fernández R, Holden JE, et al. Onset and progression of parkinsonian symptoms: a manifestation of impaired compensatory mechanisms. J Cereb Blood Flow Metab 2004; 24: 869-876.
10. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998; 51( suppl 2): S2-S9.
11. Lunardi G, Galati S, Tropepi D, et al. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease Parkinsonism Relat Disord 2009; 15: 383-389.
12. Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747-2754.
13. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612-1617.
14. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia [Review]. J Neurochem 2006; 99: 381-392.
15. de la Fuente-Fernández R, Schulzer M, Mak E, et al. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127: 888-899.
16. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-858.
17. Zigmond MJ, Hastings TG, Perez RG. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 2002; 8: 389-393.
18. Sossi V, de la Fuente-Fernández R, Schulzer M, et al. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007; 62: 468-474.
19. Sossi V, Dinelle K, Topping GJ, et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009; 109: 85-92.
20. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009; 72: 1211-1216.
21. Lee J, Zhu WM, Stanic D, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008; 131: 1574-1587.
22. Uhl GR. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 1998; 43: 555-560.
23. Mata IF, Wedemeyer WJ, Farrer MJ, et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006; 29: 286-293.
24. Sossi V, de la Fuente-Fernandez R, Schulzer M, et al. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006; 129: 1050-1058.
25. Spinks TJ, Jones T, Bailey DJ, et al. Physical performance of a positron tomography for brain imaging with retractable septa. Phys Med Biol 1992; 37: 1637-1655.
26. Sossi V, Oakes TR, Chan GL, et al. Quantitative comparison of three- and two-dimensional PET with human brain studies. J Nucl Med 1998; 39: 1714-1719.
27. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993; 17: 536-546.
28. 18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998; 29: 225-232.
29. 18F]fluoro-L-DOPA input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. Appl Rad Isot 1991; 42: 847-854.
30. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
31. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in-vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
32. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 2001; 21: 469-476.
33. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
34. Draper N, Smith H. Applied regression analysis. New York: Wiley; 1981.
35. Masuo Y, Pélaprat D, Scherman D, Rostène W. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci Lett 1990; 114: 45-50.
36. Haugarvoll K, Rademakers R, Kachergus JM, et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008; 70: 1456-1460.
37. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008; 7: 591-594.
38. 18Ffluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 2003; 23: 301-309.